Clinical Trials Directory

Trials / Completed

CompletedNCT05274646

Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A

Impact on Risk Stratification of Overlap Syndrome Phenotype (Brugada and Long QT Type 3) in Patients With E1784K Mutation in SCN5A

Status
Completed
Phase
Study type
Observational
Enrollment
47 (actual)
Sponsor
Centre Hospitalier Universitaire de la Réunion · Academic / Other
Sex
All
Age
12 Years
Healthy volunteers

Summary

In patients expressing the SCN5A-E1784K mutation (Glu1784Lys), cardiovascular risk is difficult to define as the stratification of these patients is challenging. From our experience, major cardiovascular events (MCE) tend to occur more frequently in patients expressing overlap syndrome phenotype (Brugada syndrome and Long QT syndrome type 3)than in patients expressing a single phenotype (whether Brugada syndrome or Long QT syndrome type 3). This trials is led on the impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A ( RISKOVER )

Detailed description

Study design: This study will compare the occurrence of MCE between patients with overlap syndrome phenotype and patients with a single phenotype (whether Brugada syndrome or Long QT syndrome type 3) in a cohort of patients 12 years of age and older with the SCN5A-E1784K mutation. Eligible patients will be identified nationwide and included retrospectively and prospectively. Occurrence of MCE between the group " overlap syndrome " and the group " single phenotype " will be compared.

Conditions

Timeline

Start date
2022-04-05
Primary completion
2024-03-20
Completion
2024-03-20
First posted
2022-03-10
Last updated
2025-08-05

Locations

1 site across 1 country: Reunion

Source: ClinicalTrials.gov record NCT05274646. Inclusion in this directory is not an endorsement.